Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Dixon Technologies' outperform rating is sustained by BNP Paribas India, citing remarkable FY25 results and future ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

and global Pfizer RWE leaders to explore the potential of Abu Dhabi’s Trusted Research Environment in advancing scientific discovery. This initiative is part of a broader effort under the MoU to ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...

Global pharmaceutical company Pfizer Inc. is donating $750,000 to ... praised the donation as a sign of progress in public-private partnerships. “I am honored to work alongside Pfizer and ...

While gaps persist in workforce retention, infrastructure, and equitable access, the transformation of Nigeria’s health ...

Yu Xuefeng, CEO of Chinese vaccine company CanSino Biologics, says the company remains on-track to breakeven in 2025, and remains committed to expanding into the global ... and 70 Pfizer's CEO ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...